Bone Mineral Density in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Adult Subjects Switching From a Tenofovir Regimen to a Dolutegravir Plus Rilpivirine Regimen

PHASE3CompletedINTERVENTIONAL
Enrollment

102

Participants

Timeline

Start Date

June 12, 2015

Primary Completion Date

September 16, 2016

Study Completion Date

August 17, 2018

Conditions
HIV Infections
Interventions
DRUG

Subjects do not receive study medication in this study 202094

Participants do not receive study medication in this study 202094.

Trial Locations (32)

1000

GSK Investigational Site, Brussels

1141

GSK Investigational Site, Buenos Aires

2000

GSK Investigational Site, Rosario

4000

GSK Investigational Site, Liège

9000

GSK Investigational Site, Ghent

20007

GSK Investigational Site, Washington D.C.

24501

GSK Investigational Site, Lynchburg

28040

GSK Investigational Site, Madrid

28041

GSK Investigational Site, Madrid

28046

GSK Investigational Site, Madrid

29010

GSK Investigational Site, Málaga

30003

GSK Investigational Site, Murcia

30202

GSK Investigational Site, Cartagena (Murcia)

33401

GSK Investigational Site, West Palm Beach

41013

GSK Investigational Site, Seville

63108

GSK Investigational Site, St Louis

68198

GSK Investigational Site, Omaha

90036

GSK Investigational Site, Los Angeles

94109

GSK Investigational Site, San Francisco

C1425AWK

GSK Investigational Site, Ciudad Autonoma de Buenos Aires

C1202ABB

GSK Investigational Site, Ciudad de Buenos Aires

V6Z 2T1

GSK Investigational Site, Vancouver

M5G 2N2

GSK Investigational Site, Toronto

H3A 1T1

GSK Investigational Site, Montreal

G1V 4G2

GSK Investigational Site, Québec

03010

GSK Investigational Site, Alicante

08916

GSK Investigational Site, Badalona

08035

GSK Investigational Site, Barcelona

08907

GSK Investigational Site, Barcelona

07198

GSK Investigational Site, Palma de Mallorca

E1 1BB

GSK Investigational Site, London

NW3 2QG

GSK Investigational Site, London

Sponsors
All Listed Sponsors
collaborator

Janssen Pharmaceuticals

INDUSTRY

collaborator

GlaxoSmithKline

INDUSTRY

lead

ViiV Healthcare

INDUSTRY